The Outcomes-Based Reimbursement Experiment
US payers and drug companies are showing interest in outcomes-based contracts and even implementing some but whether they will become the reimbursement arrangements of the future remains highly uncertain.
You may also be interested in...
Multiple gene therapies have been approved in the last couple of years, but market access and reimbursement for gene therapies remain challenging – a key theme of the Cell & Gene Meeting on the Mesa.
AstraZeneca and UPMC Health Plan have signed a value-based contract for Brilinta linked to cardiovascular outcomes, with UPMC agreeing to pay more if the drug outperforms expectations.
Drug makers are embracing different strategies on the pricing issue as the industry marches closer to a confrontation with President-Elect Trump over the cost of medicines.